Skip to main content Help with accessibility Skip to main navigation

Safety

Medicines Safety Assurance Tool

The Medicines Safety Assurance Tool (MSAT) is provided as a PDF document for reference. To request the spreadsheet solution of this safety tool, or for more information about this tool, to make a comment, or share a safety issue please contact mlcsu.medicines-safety@nhs.net.

The MSAT was developed to improve the management of medicines related risk to patients. It is intended to provide commissioners with a systematic way of identifying and analysing emerging medicines safety issues and engage with providers to reduce medicines related harm.

Transition of Commissioning Policies

On 1st July 2022 NHS Cheshire and Merseyside Integrated Care Board (ICB) became the new statutory body responsible for ensuring health care services are available to meet the reasonable needs of the people of Cheshire & Merseyside.

Until such time as a single suite of commissioning policies can be developed and adopted, NHS Cheshire and Merseyside will continue to adopt and operate the CCG policies it has inherited at Place/borough level, which means that there will be no immediate change in commissioning policy for local people resident in those Places/boroughs from what was in place prior to 1st July 2022.

NHS Cheshire and Merseyside Commissioning Policies

 

Coronavirus guidance

Guidance to support primary care prescribers and pharmacists is available from the MLCSU Coronavirus guidance resource page.

Documents

Date Added: 26 - Jun - 2018

Overdose of methotrexate can lead to serious adverse effects such as haematopoietic disorders (leukopenia, thrombocytopenia, anaemia, and pancytopenia) and  gastrointestinal reactions (mucositis, stomatitis, oral ulceration, gastrointestinal ulceration, and gastrointestinal bleeding). Some reports of overdose have been fatal. In  these fatal cases, events such as sepsis or septic shock, renal failure, and aplastic anaemia were reported.